Home Consultants Dr Waqar Saleem

Rutherford Location

Leave a message

Specialities

  • Bladder
  • Brain
  • Neurological
  • Non-Melanoma Basal cell carcinoma (BCC)
  • Prostate
  • Skin
  • Spinal
  • Urological

Biography

Dr Waqar Saleem is Consultant Clinical Oncologist based at the Rutherford Cancer Centre in Thames Valley. He specialises in the treatment of brain, spinal cord, prostate, bladder and skin cancers, using radiation and systemic therapies (chemotherapy, targeted agents and immunotherapy).

Dr Waqar Saleem trained on the North West London training scheme, qualifying for FRCR and obtained his Masters in Oncology from the Institute of Cancer Research. He's also an enthusiastic teacher and Oncology Unit Training Lead at the  Imperial College Healthcare NHS Trust.

He currently holds an NHS post at the Imperial College Healthcare NHS Trust. He is trained in the delivery of proton beam therapy for neurological and urological malignancies. He also delivers post-operative radiotherapy for keloid scars. He is English speaking but is also fluent in Urdu, Punjabi and Hindi.

Qualifications

  • MBBS
  • MRCP
  • MSc
  • FRCR

Professional bodies

  • Member Clinical Oncology Professional Learning & Development Committee (Royal College of Radiologists)

Memberships

  • Royal College of Radiologists, UK
  • European Association of Neurooncology

Research interests

Dr Waqar Saleem is co-investigator for a number of clinical, imaging and radiological studies available in Charing Cross Hospital, related to urological and neurological malignancies.

Areas of interest

Dr Waqar Saleem has a special interest in the management of brain secondaries and is qualified to deliver stereotactic radiosurgery and radiotherapy for these tumours using Gamma Knife and Linear Accelerators.

Publications

  • "BrainWear: Longitudinal, objective assessment of physical activity in 42 High Grade Glioma (HGG) patients" - Oral presentation British Neuro-Oncology Society Annual Meeting 2021
  • "Estimating population-based incidence of brain metastases – a comprehensive incident cohort study" - Oral presentation British Neuro-Oncology Society Annual Meeting 2021
  • Extreme hypofractionated external beam radiotherapy for prostate cancer – comparison of cyberknife & VMAT (MSc dissertation)
  • Identifying palliative radiotherapy in a national radiotherapy dataset – a single centre pilot study: poster presentation at Sharing the Vision for World-class Radiotherapy, Manchester, March 2017
  • Classification using real-world Radiotherapy Dataset – multi-institution project; submitted to Knowledge Discovery in Databases (KDD) conference February 2018
  • Prevalence of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy – results from a single institution experience: poster presentation at ASCO 2014 Genitourinary Cancers Symposium. JCO Abstract 2014:283 Vol 32 No 4 February Supplement
  • IMRT-SIB for treating the prostate and pelvic nodes in high risk localised and locally advanced prostate cancer: experience of first 100 patients: poster presentation at NCRI – Nov. 2014
    Glynne-Jones R, Saleem W, Harrison M, Mawdsley S, Hall M. Background and current treatment of squamous cell carcinoma of the anus. Oncol Ther. 2016;4(2):135-72
  • Extreme hypofractionated external beam radiotherapy for prostate cancer – comparison of cyberknife & VMAT (MSc dissertation)
  • Identifying palliative radiotherapy in a national radiotherapy dataset – a single centre pilot study: poster presentation at Sharing the Vision for World-class Radiotherapy, Manchester, March 2017
  • Classification using real-world Radiotherapy Dataset – multi-institution project; submitted to Knowledge Discovery in Databases (KDD) conference February 2018
  • Prevalence of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy – results from a single institution experience: poster presentation at ASCO 2014 Genitourinary Cancers Symposium. JCO Abstract 2014:283 Vol 32 No 4 February Supplement
  • IMRT-SIB for treating the prostate and pelvic nodes in high risk localised and locally advanced prostate cancer: experience of first 100 patients: poster presentation at NCRI – Nov. 2014
    Glynne-Jones R, Saleem W, Harrison M, Mawdsley S, Hall M. Background and current treatment of squamous cell carcinoma of the anus. Oncol Ther. 2016;4(2):135-72
  • Extreme hypofractionated external beam radiotherapy for prostate cancer – comparison of cyberknife & VMAT (MSc dissertation)
  • Identifying palliative radiotherapy in a national radiotherapy dataset – a single centre pilot study: poster presentation at Sharing the Vision for World-class Radiotherapy, Manchester, March 2017
  • Classification using real-world Radiotherapy Dataset – multi-institution project; submitted to Knowledge Discovery in Databases (KDD) conference February 2018
  • Prevalence of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy – results from a single institution experience: poster presentation at ASCO 2014 Genitourinary Cancers Symposium. JCO Abstract 2014:283 Vol 32 No 4 February Supplement
  • IMRT-SIB for treating the prostate and pelvic nodes in high risk localised and locally advanced prostate cancer: experience of first 100 patients: poster presentation at NCRI – Nov. 2014
  • Glynne-Jones R, Saleem W, Harrison M, Mawdsley S, Hall M. Background and current treatment of squamous cell carcinoma of the anus. Oncol Ther. 2016;4(2):135-72

Declaration

  1. Dr Waqar Saleem does not hold a share or financial interest in the Rutherford Cancer Centres or another Rutherford Health plc company.
  2. Dr Waqar Saleem does not have a share or financial interest in equipment used at the Rutherford Cancer Centres or another Rutherford Health plc company.
  3. Dr Waqar Saleem does not hold any paid advisory role(s) at the Rutherford Cancer Centres or on behalf of Rutherford Cancer Centres or Rutherford Health plc.

Get in Touch

If you'd like to speak to us about any of the treatments we offer please don’t hesitate to get in touch. Call us on 0800 210 0402 or

Our Trusted Healthcare Partners